TuHURA Biosciences (HURA) Q3 2026 earnings summary

Executive summary

• IFX-2.0 plus Keytruda showed major objective partial responses in the first 3 patients with deep-seated metastatic Merkel cell carcinoma; all responses remained ongoing for more than 6 months.

• FDA cleared a Phase 1b study of TBS-2025 in relapsed/refractory mutNPM1 AML; financing through the Parkview facility supports continued program development.

Financial highlights

• Q3 2026 R&D expense was $3.7M vs. $5.0M in Q3 2025, primarily due to lower manufacturing costs; manufacturing costs were expected to resume next quarter.

• Q3 2026 G&A expense was $2.0M vs. $1.6M in Q3 2025, mainly from higher non-cash stock compensation and public-company costs.

• 9M 2026 operating cash outflow was $18.1M vs. $22.1M in 9M 2025; financing cash inflow was $16.5M vs. $13.4M.

• Cash and cash equivalents were $1.9M at Sept. 30, 2026.

Outlook and guidance

• IFX-2.0: preliminary front-line study results expected in 1H 2027; Phase 3 enrollment completion expected in 2H 2027.

• TBS-2025: Phase 1b/2 trial initiation expected in 2H 2026; preliminary safety and response data and AML orphan drug designation expected in 1H 2027.

• MDSC inhibitor program: DOR research presentations at ASH and ADC in-vivo proof-of-concept studies expected in 2H 2026.